1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
(
- Contribution to journal › Article
- 2019
-
Mark
Insight into the dimer dissociation process of the Chromobacterium violaceum (S)-selective amine transaminase
(
- Contribution to journal › Article
- 2018
-
Mark
Transaminase-Catalyzed Racemization with Potential for Dynamic Kinetic Resolutions
(
- Contribution to journal › Article
- 2016
-
Mark
Cancer differentiating agent hexamethylene bisacetamide inhibits BET bromodomain proteins
(
- Contribution to journal › Article